Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8668115 | 0.98 | MAOA (0.45) | MAOAHTR2AHRH1KIF11CYP2A6 | |
| SCHEMBL577389 | 0.83 | CYP2A6 (0.43) | MAOAHTR2AHRH1CYP2A6ALDH1A1 | |
| SCHEMBL29161709 | 0.83 | LTA4H (0.49) | MAOAHRH1TSHR | |
| SCHEMBL8154332 | 0.83 | ALDH1A1 (0.48) | MAOACYP2A6ALDH1A1TSHR | |
| SCHEMBL29161712 | 0.80 | MAOB (0.44) | MAOA | |
| SCHEMBL8071620 | 0.80 | ALDH1A1 (0.37) | MAOAHTR2ACYP2A6ALDH1A1TSHR | |
| SCHEMBL1533585 | 0.79 | ALDH1A1 (0.40) | MAOACYP2A6ALDH1A1TSHR | |
| SCHEMBL1829832 | 0.78 | IDO1 (0.48) | MAOAHTR2ASIGMAR1 | |
| SCHEMBL1829833 | 0.78 | IDO1 (0.48) | MAOAHTR2ASIGMAR1 | |
| SCHEMBL38728 | 0.77 | LMNA (0.46) | CYP2A6ALDH1A1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | claimed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| WO-1998032765-A1 | SULFAMATE DERIVATIVES WITH t-RNA SYNTHETASE INHIBITING ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-07-30 | — | — | WO | claimed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| EP-0722436-A4 | MERCAPTOSULFIDE METALLOPROTEINASE INHIBITORS | UNIV FLORIDA STATE (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0722436-A1 | MERCAPTOSULFIDE METALLOPROTEINASE INHIBITORS | FLORIDA STATE UNIVERSITY (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995009833-A1 | MERCAPTOSULFIDE METALLOPROTEINASE INHIBITORS | FLORIDA STATE UNIVERSITY (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAOA 3407/4885HTR2A 4400/4885HRH1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.